US2021121568A1PendingUtilityA1

Gastrointestinal tract therapeutic agents

59
Individually held — no corporate assignee on recordPriority: Jul 26, 2012Filed: Nov 2, 2020Published: Apr 29, 2021
Est. expiryJul 26, 2032(~6 yrs left)· nominal 20-yr term from priority
Inventors:Ronald L. Moy
A61K 38/18A61K 38/43A61K 8/64A61Q 19/08A61K 9/0009A61K 9/127A61K 38/1808A61K 8/66A61K 8/14A61K 9/0014A61K 2800/82A61M 37/0092A61K 41/0047
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed is a method of preventing or treating a condition of the gastrointestinal tract. The method includes the steps of providing a DNA repair composition, the DNA repair composition comprising at least one DNA repair enzyme, the DNA repair composition configured for administration within the gastrointestinal tract of a patient; and administering the DNA repair composition to the patient, such that the DNA repair composition is absorbed within the gastrointestinal tract of the patient to treat the condition of the gastrointestinal tract.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of preventing or treating a condition of the gastrointestinal tract, comprising:
 providing a DNA repair composition, the DNA repair composition comprising at least one DNA repair enzyme, the DNA repair composition configured for administration within the gastrointestinal tract of a patient; and   administering the DNA repair composition to the patient, such that the DNA repair composition is absorbed within the gastrointestinal tract of the patient to treat the condition of the gastrointestinal tract.   
     
     
         2 . The method of  claim 1 , wherein administering comprising orally administering the DNA repair composition. 
     
     
         3 . The method of  claim 1 , wherein administering comprising rectally administering the DNA repair composition. 
     
     
         4 . The method of  claim 1 , wherein the DNA repair composition is absorbed primarily within the oropharynx of the patient. 
     
     
         5 . The method of  claim 1 , wherein the DNA repair composition is absorbed primarily within the esophagus of the patient. 
     
     
         6 . The method of  claim 1 , wherein the DNA repair composition is absorbed primarily within the stomach of the patient. 
     
     
         7 . The method of  claim 1 , wherein the DNA repair composition is absorbed primarily within the small intestine of the patient. 
     
     
         8 . The method of  claim 1 , wherein the DNA repair composition is absorbed primarily within the colon of the patient. 
     
     
         9 . The method of  claim 1 , wherein the DNA repair composition is absorbed primarily within the anorectal region of the patient. 
     
     
         10 . The method of  claim 1 , wherein the DNA repair composition is pH sensitive. 
     
     
         11 . The method of  claim 1 , wherein the condition is an oropharnygeal ulcer. 
     
     
         12 . The method of  claim 1 , wherein the condition is Barrett's esophagus. 
     
     
         13 . The method of  claim 1 , wherein the condition is peptic ulcer disease. 
     
     
         14 . The method of  claim 1 , wherein the condition is dysplasia of the endothelial lining. 
     
     
         15 . The method of  claim 1 , wherein the condition is a polyp. 
     
     
         16 . The method of  claim 1 , wherein the condition is inflammatory bowel disease. 
     
     
         17 . The method of  claim 1 , wherein the condition is carcinoma. 
     
     
         18 . The method of  claim 1 , wherein the DNA repair enzyme is selected from the group consisting of: endonuclease V, O6-methylguanine-DNA methyltransferases, photolyases, uracil- and hypoxanthine-DNA glycosylases, apyrimidinic/apurinic endonucleases, DNA exonucleases, damaged-bases glycosylases, and correndonucleases 
     
     
         19 . A therapeutic agent for preventing or treating a condition of the gastrointestinal tract, comprising:
 a DNA repair composition, the DNA repair composition comprising at least one DNA repair enzyme, the DNA repair composition configured for oral administration within the gastrointestinal tract of a patient and configured to be absorbed within the gastrointestinal tract of the patient to effect DNA repair of at least a portion of the lining of the gastrointestinal tract.   
     
     
         20 . The therapeutic agent of  claim 19 , wherein the DNA repair enzyme is selected from the group consisting of: endonuclease V, O6-methylguanine-DNA methyltransferases, photolyases, uracil- and hypoxanthine-DNA glycosylases, apyrimidinic/apurinic endonucleases, DNA exonucleases, damaged-bases glycosylases, and correndonucleases.

Join the waitlist — get patent alerts

Track US2021121568A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.